In this respect, the programmed death-1 (PD1) and cytotoxic T-lymphocyte associated antigen-4 (CTLA4) immune checkpoints are major resources against metastatic melanoma [2,3,4], as a standard treatment and in the adjuvant setting [5,6,7]. Here, CTLA4 is linked to metastatic melanoma.